Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock

Toni Jäntti, Tuukka Tarvasmäki, Veli Pekka Harjola, John Parissis, Kari Pulkki, Alessandro Sionis, Jose Silva-Cardoso, Lars Køber, Marek Banaszewski, Jindrich Spinar, Valentin Fuhrmann, Jukka Tolonen, Valentina Carubelli, Salvatore diSomma, Alexandre Mebazaa, Johan Lassus, Katerina Koniari, Astrinos Voumvourakis, Apostolos Karavidas, Jordi Sans-RoselloMontserrat Vila, Albert Duran-Cambra, Marco Metra, Michela Bulgari, Valentina Lazzarini, Jiri Parenica, Roman Stipal, Ondrej Ludka, Marie Palsuva, Eva Ganovska, Petr Kubena, Matias G. Lindholm, Christian Hassager, Tom Bäcklund, Raija Jurkko, Kristiina Järvinen, Tuomo Nieminen, Kari Pulkki, Leena Soininen, Reijo Sund, Ilkka Tierala, Jukka Tolonen, Marjut Varpula, Tuomas Korva, Anne Pitkälä, Rossella Marino, Alexandra Sousa, Carla Sousa, Mariana Paiva, Inês Rangel, Rui Almeida, Teresa Pinho, Maria Júlia Maciel, Janina Stepinska, Anna Skrobisz, Piotr Góral

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)


© 2017 Elsevier Inc. Cardiogenic shock (CS) is a cardiac emergency often leading to multiple organ failure and death. Assessing organ dysfunction and appropriate risk stratification are central for the optimal management of these patients. The purpose of this study was to assess the prevalence of abnormal liver function tests (LFTs), as well as early changes of LFTs and their impact on outcome in CS. We measured LFTs in 178 patients in CS from serial blood samples taken at 0 hours, 12 hours, and 24 hours. The associations of LFT abnormalities and their early changes with all-cause 90-day mortality were estimated using Fisher's exact test and Cox proportional hazards regression analysis. Baseline alanine aminotransferase (ALT) was abnormal in 58% of the patients, more frequently in nonsurvivors. Abnormalities in other LFTs analyzed (alkaline phosphatase, gamma-glutamyl transferase, and total bilirubin) were not associated with short-term mortality. An increase in ALT of >20% within 24 hours (ΔALT>+20%) was observed in 24% of patients. ΔALT>+20% was associated with a more than 2-fold increase in mortality compared with those with stable or decreasing ALT (70% and 28%, p <0.001). Multivariable regression analysis showed that ΔALT>+20% was associated with increased 90-day mortality independent of other known risk factors. In conclusion, an increase in ALT in the initial phase was seen in 1/4 of patients in CS and was independently associated with 90-day mortality. This finding suggests that serial ALT measurements should be incorporated in the clinical assessment of patients in CS.
Original languageEnglish
Pages (from-to)1090-1097
JournalAmerican Journal of Cardiology
Issue number7
Publication statusPublished - 1 Oct 2017


Dive into the research topics of 'Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock'. Together they form a unique fingerprint.

Cite this